View Older Stories View More Recent Stories

Sep 3, 2018 05:12AM Total voting rights
Sep 3, 2018 02:00AM Total voting rights
Aug 29, 2018 07:00AM Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Aug 16, 2018 07:00AM Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Aug 6, 2018 07:00AM Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Aug 2, 2018 02:00PM Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
Jul 10, 2018 03:00AM Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Jun 27, 2018 07:00AM Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
Jun 15, 2018 07:00AM Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
Jun 11, 2018 07:00AM Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
Jun 5, 2018 07:00AM Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress
Jun 1, 2018 07:00AM Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018
Apr 23, 2018 07:00AM Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
Apr 23, 2018 06:45AM Award of Share Options and Restricted Stock Units
Apr 20, 2018 07:00AM Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
Apr 19, 2018 07:00AM Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
Apr 11, 2018 07:00AM Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress
Apr 9, 2018 10:01AM Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018
Apr 5, 2018 07:00AM Summit Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Mar 28, 2018 07:00AM Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
Mar 14, 2018 07:00AM Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference
Mar 13, 2018 07:00AM Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
Mar 7, 2018 07:00AM Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
Feb 26, 2018 07:00AM Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
Feb 23, 2018 07:00AM Summit Therapeutics to Participate in 2018 BTIG Healthcare Conference
Feb 9, 2018 07:00AM Summit Therapeutics to Participate in Upcoming Investor Conferences
Jan 25, 2018 07:07AM Summit Therapeutic (SMMT) Says Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data from PhaseOut DMD Clinical Trial
Jan 25, 2018 07:00AM Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
Jan 9, 2018 07:00AM Summit Therapeutics to Present at the Biotech Showcase
Dec 23, 2017 04:00PM Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
Dec 21, 2017 02:00AM Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
Dec 6, 2017 07:00AM Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress
Dec 6, 2017 02:00AM Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
Dec 4, 2017 07:00AM Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017
Nov 22, 2017 07:00AM Summit Therapeutics to Participate in Upcoming Investor Conferences
Nov 20, 2017 07:05AM Ayretrade, Inc. (SUMM) Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
Nov 20, 2017 07:00AM Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial
Nov 9, 2017 07:00AM Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
Nov 6, 2017 09:29AM Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole
Oct 25, 2017 09:00AM Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive Directors
Oct 9, 2017 07:00AM Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
Oct 4, 2017 07:00AM Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
Oct 2, 2017 07:00AM Summit Therapeutics to Host R&D Day 11 October 2017
Sep 25, 2017 07:00AM Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
Sep 11, 2017 07:00AM Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
Sep 5, 2017 07:02AM Ayretrade, Inc. (SUMM) Announces Positive Phase 2 Ridinilazole Top-Line Data for CDI
Sep 5, 2017 07:00AM Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
Aug 31, 2017 07:00AM Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progress
Aug 25, 2017 09:30AM Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017
Aug 3, 2017 07:00AM Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
View More Recent Stories View Older Stories